Last updated: September 27, 2026
Zafirlukast is an off-patent, small-molecule leukotriene receptor antagonist marketed primarily as 10 mg and 20 mg immediate-release oral tablets. The commercial opportunity is no longer based on molecule exclusivity. It is concentrated in reliable dissolution, food-effect control, cost-efficient tablet manufacture, differentiated dosage forms, and supply of compliant excipients for generic and regional products.
The reference product, Accolate, contains zafirlukast and a conventional tablet excipient system that includes lactose, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, hypromellose and color or opacifying agents, depending on strength and market presentation. Zafirlukast has low aqueous solubility and clinically relevant food-related absorption effects, making formulation control important even though the product is technically an immediate-release tablet (FDA, 2024a; AstraZeneca, 2012).
What is zafirlukast and how is it regulated?
Zafirlukast is an oral cysteinyl leukotriene receptor antagonist indicated for prophylaxis and chronic treatment of asthma. It is not intended for acute bronchospasm. The U.S. reference product was approved under NDA 020547, and generic products may be approved through abbreviated new drug applications if they demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug (FDA, 2024a).
FDA regulatory status
| Attribute |
Zafirlukast |
| Active ingredient |
Zafirlukast |
| Therapeutic class |
Leukotriene receptor antagonist |
| Main dosage forms |
Immediate-release tablets |
| Common strengths |
10 mg and 20 mg |
| Reference product |
Accolate |
| U.S. reference NDA |
NDA 020547 |
| Regulatory pathway for generics |
ANDA |
| Biologic status |
Small molecule; biosimilar pathway does not apply |
| Key administration instruction |
Take on an empty stomach, at least one hour before or two hours after meals |
| Principal formulation issue |
Low solubility and food-related exposure variability |
Zafirlukast carries a hepatotoxicity warning and has clinically relevant drug-interaction considerations, including interaction with warfarin. Excipients cannot be used to address these pharmacological risks. Their role is to support dose uniformity, dissolution, stability, manufacturability and patient acceptability.
What excipients are used in zafirlukast tablets?
The reference formulation uses a conventional direct-compression or wet-granulation-compatible excipient platform. Public labeling identifies lactose, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, hypromellose and titanium dioxide or other presentation-specific colorants among the inactive ingredients (FDA, 2024a; DailyMed, 2024).
Functional role of the principal excipients
| Excipient |
Primary function |
Strategic relevance |
| Lactose monohydrate |
Diluent and tablet bulk |
Low cost and established regulatory history; requires assessment of lactose intolerance and supplier consistency |
| Microcrystalline cellulose |
Filler, dry binder and compression aid |
Supports tablet strength and robust high-speed compression |
| Croscarmellose sodium |
Superdisintegrant |
Important for rapid tablet breakup and immediate-release dissolution |
| Povidone |
Binder and granulation aid |
Supports granule strength and content uniformity |
| Magnesium stearate |
Lubricant |
Reduces ejection force; excess levels or prolonged blending can impair wetting and dissolution |
| Hypromellose |
Film former |
Improves handling, appearance and moisture protection |
| Titanium dioxide or colorants |
Opacifier and color control |
Supports product identification but creates regional regulatory and consumer-acceptance considerations |
The principal formulation tradeoff is between mechanical robustness and rapid dissolution. Zafirlukast formulations that use too much hydrophobic lubricant, excessive binder or overly dense granules may pass basic tablet specifications while producing slower dissolution. The design target should be an immediate-release profile with adequate margin across compression force, lubricant blending time, granule moisture and manufacturing scale.
Why does zafirlukast require an excipient-focused formulation strategy?
Zafirlukast is a poorly water-soluble drug. Public scientific databases classify the compound as having limited aqueous solubility, while product labeling requires administration away from food because food changes systemic exposure (PubChem, 2024; FDA, 2024a).
Solubility and dissolution
The main technical question is not whether a tablet disintegrates. It is whether the drug dissolves consistently after disintegration. The formulation team should evaluate:
- Particle-size distribution and specific surface area of the active ingredient.
- Wetting behavior in the selected diluent system.
- Disintegrant type, concentration and intragranular or extragranular placement.
- Lubricant concentration and blending duration.
- Dissolution performance across physiologically relevant pH conditions.
- Compression-force sensitivity.
- Stability under humidity and elevated temperature.
A simple lactose-microcrystalline cellulose system may be commercially attractive because it is inexpensive, widely available and familiar to generic manufacturers. It may not provide the best dissolution margin if the active ingredient has large particles, poor wetting or a hydrophobic surface.
Food-effect limitations
The empty-stomach dosing instruction limits the value of a formulation strategy that merely increases drug loading or tablet hardness. A reformulated product could seek less food-sensitive exposure, but such a product may require clinical bridging, a new regulatory strategy or a different bioequivalence approach. The commercial value of that development depends on whether the sponsor can demonstrate meaningful adherence or efficacy benefits.
Excipient selection can improve dissolution robustness, but it cannot be assumed to eliminate the clinical food effect. Any claim of reduced food sensitivity would require comparative pharmacokinetic evidence.
What is the best immediate-release excipient platform for zafirlukast?
A practical baseline is a lactose and microcrystalline cellulose diluent system with croscarmellose sodium as the primary disintegrant, povidone as a binder where needed, and magnesium stearate at the lowest level that provides acceptable manufacturability.
Recommended development architecture
Baseline generic platform
The lowest-risk platform would use:
- Lactose monohydrate or an alternative soluble diluent.
- Microcrystalline cellulose for compactability.
- Croscarmellose sodium for rapid breakup.
- Povidone only at the level required for granule or tablet strength.
- Magnesium stearate with controlled blending time.
- A thin hypromellose film coat.
This platform is commercially defensible where the goal is an economical ANDA product with low process complexity.
Direct compression
Direct compression can reduce processing steps and water exposure. It is attractive if the active ingredient has acceptable flow and blend uniformity. The main risks are segregation, poor content uniformity at low drug loading and sensitivity to compression force.
A 10 mg strength may present greater blend-uniformity risk than the 20 mg strength because the active represents a smaller proportion of total tablet mass. Content-uniformity data should therefore be generated separately for each strength rather than extrapolated solely from formulation proportionality.
Wet granulation
Wet granulation can improve flow, compressibility and content uniformity. It may be preferable if the active has poor flow or if direct compression produces variable hardness and dissolution. The process introduces additional risks, including overwetting, drug migration, residual moisture and granule densification.
A low-shear or controlled aqueous granulation process may be suitable, but the formulation should be tested for chemical and physical stability under the selected drying conditions.
Solubility-enhanced systems
More advanced approaches could use:
- Surfactant-assisted wetting.
- Spray-dried solid dispersions.
- Amorphous solid dispersions.
- Co-milled active ingredient.
- Nanocrystalline drug substance.
- Lipid-based or self-emulsifying systems.
These technologies may increase dissolution, but they also raise manufacturing, stability, scale-up and regulatory complexity. For an off-patent asthma product, they are commercially attractive only if they produce a clear benefit, such as improved bioequivalence margin, lower dose variability or a differentiated dosage form.
What formulation patents protect zafirlukast products?
The core zafirlukast molecule and original Accolate formulation are no longer credible barriers to routine U.S. generic development. The commercial focus has shifted from molecule patents to formulation know-how, manufacturing controls, trademarks, regulatory data and market access.
Patent and exclusivity position
| Protection category |
Commercial assessment |
| Core compound patent |
Historical protection; no longer a practical barrier to standard generic entry |
| Original tablet formulation |
Historical protection; standard formulation entry is available |
| Orange Book-listed patents |
Must be checked against the current FDA Orange Book and relevant product record before launch |
| Method-of-use patents |
Limited relevance for a mature asthma product unless tied to a specific new use |
| Formulation patents |
Potentially relevant only for differentiated delivery, taste masking, food-effect reduction or novel dosage forms |
| Regulatory exclusivity |
Original exclusivity has expired |
| Biosimilar exclusivity |
Not applicable |
Patent protection can still matter for a new formulation, such as an orally disintegrating tablet, pediatric granule, modified-release product or food-effect-reduced formulation. A generic manufacturer should not assume that the absence of meaningful core-molecule protection eliminates all freedom-to-operate issues. Formulation patent searches should cover zafirlukast solid dispersions, particle engineering, salts, polymorphs, liquid suspensions, film coatings and combination products.
When did zafirlukast lose exclusivity?
Zafirlukast lost the commercial value of its original U.S. exclusivity years ago. Accolate was approved in 1996, and the product is now a mature small-molecule generic opportunity rather than an originator-protected asset (FDA, 1996; FDA, 2024b).
The relevant current barriers are:
- ANDA development and approval timing.
- Availability of qualified active pharmaceutical ingredient.
- Bioequivalence performance.
- Manufacturing economics.
- Distribution access.
- Product discontinuation or shortage dynamics.
- State and payer substitution rules.
- Any surviving jurisdiction-specific formulation or use claims.
Because exclusivity has expired, the value of a new zafirlukast excipient system must come from performance or market access, not from extending the original molecule’s exclusivity.
What commercial opportunities exist for zafirlukast excipients?
1. Generic tablet supply
The largest near-term opportunity is supply of standard pharmaceutical excipients to generic manufacturers. Demand is likely to favor established compendial grades with consistent particle size, moisture, flow and compressibility.
The most commercially relevant materials are:
- Direct-compression lactose.
- Microcrystalline cellulose with controlled bulk density.
- Croscarmellose sodium with reproducible swelling performance.
- Low-moisture povidone.
- Magnesium stearate with controlled specific surface area.
- Hypromellose film-coating systems.
Suppliers can compete through technical documentation, dual sourcing, lower variability and supply reliability rather than novel chemistry.
2. Lactose-free and low-allergen formulations
Lactose replacement creates a modest differentiation opportunity. Potential alternatives include mannitol, dibasic calcium phosphate, starch-derived fillers and selected spray-dried composite excipients.
A lactose-free product may appeal to patients or markets where lactose labeling is commercially sensitive. The substitute must preserve tablet hardness, disintegration, dissolution and content uniformity. Mannitol may improve mouthfeel for orally disintegrating products but can increase cost and require different compression optimization.
3. Orally disintegrating tablets
An orally disintegrating zafirlukast product could improve administration for patients with swallowing difficulty. The main technical obstacles are drug taste, dose loading and dissolution performance.
Potential excipient systems include mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, sweeteners and flavors. Taste masking may require coating, complexation or particle engineering. A 20 mg dose is feasible for an ODT, but the product would require careful control of mouthfeel and residual grittiness.
4. Pediatric dosage forms
Zafirlukast is used in pediatric asthma, but a conventional tablet is not suitable for every child. A dispersible tablet, granule or oral powder could address administration barriers.
The commercial case is limited by the need to establish dose flexibility, stability after reconstitution or dispersion, palatability and bioequivalence. A pediatric formulation could be more defensible than another standard tablet, but it would carry higher development and regulatory costs.
5. Excipient and process intellectual property
The strongest potential IP positions are likely to involve a defined combination of:
- Particle-size-controlled zafirlukast.
- A specific dissolution-enhancing excipient ratio.
- A narrow process window.
- A defined solid-state form.
- A clinically supported reduction in food-related exposure variability.
- A pediatric or orally disintegrating presentation.
A broad claim covering ordinary lactose, microcrystalline cellulose and croscarmellose sodium would likely face validity and obviousness challenges. Narrow claims tied to measurable dissolution, stability or pharmacokinetic performance would have a stronger commercial rationale.
Which companies are challenging zafirlukast exclusivity?
Zafirlukast is a mature generic product. The relevant competitors are generic manufacturers and regional pharmaceutical companies rather than biosimilar developers. Public FDA product records identify approved generic zafirlukast products and their application holders, but supplier and market status can change through discontinuations, transfers and manufacturing-site changes (FDA, 2024b; FDA, 2024c).
The competitive landscape should be assessed by:
- Number of active ANDA holders.
- Current commercial availability of 10 mg and 20 mg strengths.
- Authorized generic or private-label supply.
- API source concentration.
- Current shortage or discontinuation records.
- Wholesale acquisition cost and reimbursement.
- State-level substitution status.
A product with few active suppliers may have better entry economics even when demand is modest. A product with many approved ANDAs may still offer opportunities if competitors have poor availability, inconsistent supply or limited dosage-form coverage.
What generic entry risks exist for zafirlukast?
Technical risks
The main technical risks are failed dissolution, food-related pharmacokinetic differences, blend nonuniformity, lubricant sensitivity and stability under humidity.
Regulatory risks
FDA review may focus on:
- Pharmaceutical equivalence.
- Dissolution method suitability.
- Strength proportionality.
- Inactive-ingredient safety.
- Bioequivalence under the required fasting conditions.
- Labeling consistency.
- Manufacturing-site compliance.
Inactive ingredients should be selected from FDA-permitted and compendial sources where possible. The FDA Inactive Ingredient Database can support precedent analysis, but precedent does not replace formulation-specific safety and regulatory assessment (FDA, 2024d).
Commercial risks
Zafirlukast competes with inhaled corticosteroids, combination inhalers, montelukast and other asthma therapies. Montelukast has greater market familiarity and broader use in allergic rhinitis, while inhaled products are often preferred for controller therapy. This limits the achievable price and volume for a new zafirlukast product.
How does zafirlukast compare with montelukast?
| Factor |
Zafirlukast |
Montelukast |
| Drug class |
Leukotriene receptor antagonist |
Leukotriene receptor antagonist |
| Main dosage forms |
Tablets |
Tablets, chewables, granules |
| Food instruction |
Empty-stomach administration is required |
Product- and strength-specific instructions |
| Formulation opportunity |
Dissolution control, ODT, pediatric formats |
Larger established dosage-form market |
| Commercial competition |
Mature and narrower |
Broader generic and branded competition |
| Excipient differentiation |
Potentially meaningful because of food effect and low solubility |
Often focused on taste, chewability and dosage-form convenience |
| Biosimilar risk |
Not applicable |
Not applicable |
Montelukast is the stronger volume benchmark. Zafirlukast may still support niche opportunities where suppliers can solve administration, availability or regional formulation needs.
What is the commercial value of a new zafirlukast excipient strategy?
The highest-value strategy is a staged program:
- Develop a low-cost conventional immediate-release tablet using established excipients.
- Establish dissolution and stability margins across two strengths.
- Evaluate lactose-free and direct-compression variants.
- Screen an ODT or dispersible formulation only if a target market supports differentiation.
- Protect process and formulation know-how where the performance benefit is measurable.
- Use dual-source excipients and API controls to reduce supply interruption risk.
A conventional generic product is most likely to generate value through efficient manufacturing and reliable supply. A novel excipient system can command greater commercial interest only if it improves patient administration, reduces pharmacokinetic variability or unlocks a market not served by existing tablets.
Key Takeaways
- Zafirlukast is an off-patent small molecule with no biosimilar pathway.
- The principal formulation issue is low solubility combined with a clinically relevant food effect.
- Lactose, microcrystalline cellulose, croscarmellose sodium, povidone and magnesium stearate provide a practical baseline excipient platform.
- Lubricant level, granulation density, particle size and compression force can materially affect dissolution.
- Standard generic tablets offer the lowest regulatory and manufacturing risk.
- Lactose-free, orally disintegrating, dispersible and pediatric products offer more differentiated opportunities.
- New formulation patents would need narrow, performance-linked claims to have meaningful commercial value.
- Generic competition is mature, so reliable supply and manufacturing economics are more important than molecule exclusivity.
- Zafirlukast has weaker volume prospects than montelukast but may support targeted regional and dosage-form opportunities.
FAQs
Can zafirlukast be formulated as an orally disintegrating tablet?
Yes. An ODT could use mannitol, crospovidone or croscarmellose sodium, taste-masking technology and a low-moisture manufacturing process. Bioequivalence, palatability and dissolution would determine commercial viability.
Which excipient is most important for zafirlukast dissolution?
No single excipient controls performance. Croscarmellose sodium, active-particle size, wetting, lubricant level and tablet porosity collectively determine release.
Is lactose-free zafirlukast commercially attractive?
It may be attractive in selected markets, but the opportunity is niche. A lactose-free formulation must demonstrate comparable content uniformity, dissolution, stability and manufacturability.
Does zafirlukast have biosimilar competition?
No. Zafirlukast is a chemically synthesized small molecule. Competition proceeds through generic drug applications, not biosimilar applications.
Can an excipient change remove the empty-stomach dosing requirement?
Not without supporting pharmacokinetic evidence and regulatory acceptance. Excipient changes may improve dissolution but do not automatically eliminate the labeled food-effect instruction.
References
-
AstraZeneca. (2012). Accolate (zafirlukast) tablets: U.S. prescribing information. AstraZeneca Pharmaceuticals LP.
-
DailyMed. (2024). Zafirlukast tablet, film coated: Inactive ingredients and labeling. U.S. National Library of Medicine.
-
Food and Drug Administration. (1996). Accolate approval letter and prescribing information, NDA 020547. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024a). Zafirlukast prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024c). Drugs@FDA: Zafirlukast product and application records. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024d). Inactive Ingredient Database. U.S. Department of Health and Human Services.
-
National Center for Biotechnology Information. (2024). PubChem compound summary: Zafirlukast. National Library of Medicine.
